Ziad Khatib
Pediatric Hematology-Oncology · Miami, FLNPI 1902915820
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.7% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations.
Across 82 payments — averaging $28.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sobi, Inc$397
- Novartis$354
- Novo Nordisk$167
- Amgen$162
- Bayer$147
- Day One Biopharmaceuticals$134
- plus $966 from 23 others
Across 21 payments — averaging $46,586 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$775K
- Jazz Pharmaceuticals Inc.$145K
- Eli Lilly$26K
- AstraZeneca$15K
- Springworks Therapeutics, Inc.$12K
- Alnylam Pharmaceuticals Inc.$5K
What the payments were for
- Food & beverage$2,18094%
- Education$1476%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sobi, Inc | 8 | $397 |
| Novartis | 16 | $354 |
| Novo Nordisk | 7 | $167 |
| Amgen | 3 | $162 |
| Bayer | 5 | $147 |
| Day One Biopharmaceuticals | 5 | $134 |
| Genentech USA, Inc. | 4 | $109 |
| Pfizer | 3 | $90 |
| AstraZeneca | 1 | $87 |
| Springworks Therapeutics, Inc. | 4 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $62 |
| Bard Peripheral Vascular, Inc. | 1 | $59 |
| Astellas Pharma US Inc | 2 | $57 |
| Genetix Biotherapeutics Inc | 1 | $52 |
| Sanofi | 2 | $44 |
| USWM, LLC | 2 | $43 |
| Agios Pharmaceuticals, Inc. | 2 | $34 |
| HEMA Biologics, LLC | 2 | $33 |
| Octapharma USA, Inc. | 1 | $31 |
| Servier Pharmaceuticals LLC | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| RARE Disease Therapeutics, Inc. | 1 | $22 |
| Pharming Healthcare, Inc. | 1 | $20 |
| Emmaus Medical, Inc. | 1 | $19 |
| CSL Behring | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| BTG International Inc. | 1 | $16 |
| Biomarin Pharmaceutical Inc. | 1 | $15 |
| AbbVie | 1 | $11 |
How this compares
$2,327 in reported general payments places this provider in the 65th percentile of 132 pediatric hematology-oncology providers in Florida.
See all pediatric hematology-oncology providers in Florida →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KoselugoSelumetinib Sulfate | 13 | $283,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaKoselugo | $87 | $283,37713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 132 pediatric hematology-oncology providers in Florida.
Other pediatric hematology-oncology in Miami
- Guillermo DeanguloMiami$929K
- Joanna DavisMiami$411K
- Fernando Corrales-MedinaMiami$335K
- Rachel KronenfeldMiami$40K
- Maggie FaderMiami$11K
- Ofelia AlvarezMiami$9K
- Julio BarredoMiami$8K
- Jorge Galvez SilvaMiami$7K
- Ossama MaherMiami$6K
- Sasha InclanMiami$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.